Alopecia areata after COVID-19 vaccination: two cases and review of the literature
HTML: 401
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Alopecia Areata (AA) is an autoimmune disorder characterized by hair loss, due to a T-lymphocyte-mediated inflammatory response targeting anagen-phase hair follicles. Former studies have suggested that vaccination and viral infections may play a role in the onset of AA through a variety of different mechanisms. We report here two cases of AA following COVID-19 vaccination.
Chu CH, Cheng YP, Chan JY. Alopecia Areata After Vaccination: Recurrence with Rechallenge. Pediatr Dermatol 2016;33:e218-9. DOI: https://doi.org/10.1111/pde.12849
Richardson CT, Hayden MS, Gilmore ES, Poligone B. Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. Am J Clin Dermatol 2018;19:119-26. DOI: https://doi.org/10.1007/s40257-017-0312-y
May Lee M, Bertolani M, Pierobon E, et al. Alopecia areata following COVID-19 vaccination: vaccine-induced autoimmunity? Int J Dermatol 2022 Feb 2. doi: 10.1111/ijd.16113. [Epub ahead of print]. DOI: https://doi.org/10.1111/ijd.16113
Scollan ME, Breneman A, Kinariwalla N, et al. Alopecia areata after SARSCoV-2 vaccination. JAAD Case Rep 2022;20:1-5. DOI: https://doi.org/10.1016/j.jdcr.2021.11.023
Rossi A, Magri F, Michelini S, et al. Recurrence of alopecia areata after covid-19 vaccination: A report of three cases in Italy. J Cosmet Dermatol 2021;20:3753-7. DOI: https://doi.org/10.1111/jocd.14581
Essam R, Ehab R, Al-Razzaz R, et al. Alopecia areata after ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca): a potential triggering factor? J Cosmet Dermatol 2021;20:3727-9. DOI: https://doi.org/10.1111/jocd.14459
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.